Search Result

Pathways Recommended:	Cell Cycle/DNA Damage

Results for "

reduces renal damage

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) AMPK (1) Apoptosis (6) Autophagy (1) Bacterial (1) Biochemical Assay Reagents (1) Calcium Channel (1) Caspase (3) Cytochrome P450 (1) DNA/RNA Synthesis (2) Drug Derivative (1) Elastase (1) Endogenous Metabolite (1) Farnesyl Transferase (1) Fatty Acid Synthase (FASN) (1) Fc Receptor (FcR) (1) Ferroptosis (2) Fungal (1) Guanylate Cyclase (1) Heme Oxygenase (HO) (1) HIF/HIF Prolyl-Hydroxylase (2) IFNAR (2) Influenza Virus (1) Integrin (1) Interleukin Related (3) IRE1 (1) JAK (1) JNK (1) Keap1-Nrf2 (2) MDM-2/p53 (2) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) mTOR (2) NF-κB (1) NOD-like Receptor (NLR) (3) p38 MAPK (1) PROTACs (1) Pyroptosis (2) Reactive Oxygen Species (ROS) (6) Reference Standards (1) Sirtuin (1) STAT (1) Stearoyl-CoA Desaturase (SCD) (1) STING (1) TGF-beta/Smad (1) TNF Receptor (2) TRP Channel (2) Xanthine Oxidase (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (5) Endocrinology (4) Infection (2) Inflammation/Immunology (15) Metabolic Disease (9) Neurological Disease (5)

By Targets:

Akt (1)

AMPK (1)

Apoptosis (6)

Autophagy (1)

Bacterial (1)

Biochemical Assay Reagents (1)

Calcium Channel (1)

Caspase (3)

Cytochrome P450 (1)

DNA/RNA Synthesis (2)

Drug Derivative (1)

Elastase (1)

Endogenous Metabolite (1)

Farnesyl Transferase (1)

Fatty Acid Synthase (FASN) (1)

Fc Receptor (FcR) (1)

Ferroptosis (2)

Fungal (1)

Guanylate Cyclase (1)

Heme Oxygenase (HO) (1)

HIF/HIF Prolyl-Hydroxylase (2)

IFNAR (2)

Influenza Virus (1)

Integrin (1)

Interleukin Related (3)

IRE1 (1)

JAK (1)

JNK (1)

Keap1-Nrf2 (2)

MDM-2/p53 (2)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (1)

mTOR (2)

NF-κB (1)

NOD-like Receptor (NLR) (3)

p38 MAPK (1)

PROTACs (1)

Pyroptosis (2)

Reactive Oxygen Species (ROS) (6)

Reference Standards (1)

Sirtuin (1)

STAT (1)

Stearoyl-CoA Desaturase (SCD) (1)

STING (1)

TGF-beta/Smad (1)

TNF Receptor (2)

TRP Channel (2)

Xanthine Oxidase (1)

By Research Areas:

Cancer (7)

Cardiovascular Disease (5)

Endocrinology (4)

Infection (2)

Inflammation/Immunology (15)

Metabolic Disease (9)

Neurological Disease (5)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0639

Amifostine 10+ Cited Publications WR2721	MDM-2/p53 HIF/HIF Prolyl-Hydroxylase	Cancer
Amifostine (WR2721) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine selectively protects normal tissues from damage caused by radiation and chemotherapy. Amifostine is potent hypoxia-inducible factor-α1 (HIF-α1) and p53 inducer. Amifostine protects cells from damage by scavenging oxygen-derived free radicals. Amifostine reduces renal toxicity and has antiangiogenic action .

HY-N0321

Caftaric acid trans-Caftaric acid	Others	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Caftaric acid (trans-Caftaric acid) is a polyphenolic antidiuretic, antioxidant and anti-apoptotic agent that can be hydrolyzed by intestinal microbial esterases. Caftaric acid exerts its antioxidant and potential anti-inflammatory effects mainly through intestinal microbial metabolism. Caftaric acid can reduce renal damage, restore electrolyte balance, renal function indicators and antioxidant enzyme activities in a rat albinism model, and further exert anti-oxidative stress and anti-inflammatory activities .

HY-W019894

Manganese chloride 1 Publications Verification Manganese dichloride	Biochemical Assay Reagents Apoptosis mTOR	Cardiovascular Disease Neurological Disease
Manganese chloride is an orally active MRI liver contrast agent. Manganese chloride induces Apoptosis and activates the mTOR signaling pathway. Manganese chloride induces cognitive impairment, promotes hematopoietic recovery, and reduces radiation-induced bone marrow and brain damage. It can be used for the study of renal impairment .

HY-113298

Citraconic acid 4 Publications Verification Methylmaleic acid	NOD-like Receptor (NLR) Keap1-Nrf2 Reactive Oxygen Species (ROS)	Cardiovascular Disease Inflammation/Immunology
Citraconic acid (Methylmaleic acid) is an orally active inhibitor targeting the NLRP3 inflammasome and Keap1-Nrf2 pathway. Citraconic acid reduces reactive oxygen species (ROS) generation by inhibiting succinate dehydrogenase (SDH) activity. Citraconic acid also modifies the conformation of Keap1 protein, relieves its inhibition of Nrf2, promotes antioxidant gene expression, and inhibits NLRP3 activation and the release of pro-inflammatory factors such as IL-1β and IL-18. Citraconic acid has anti-inflammatory and antioxidant activities, can reduce oxidative stress and cell pyroptosis, improve tissue damage, and can be used for the research of inflammation-related diseases such as acute renal ischemia-reperfusion injury. Citraconic acid is an isomer of Itaconic acid (HY-Y052) .

HY-155033

SSI-4	Stearoyl-CoA Desaturase (SCD) DNA/RNA Synthesis Apoptosis Autophagy mTOR Influenza Virus	Metabolic Disease Inflammation/Immunology Cancer
SSI-4 is an orally active stearoyl-CoA desaturase (SCD1) inhibitor with an EC₅₀ of 1.9 nM against mouse SCD1. SSI-4 blocks the conversion of saturated fatty acids to monounsaturated fatty acids, reducing the production of oleic acid and palmitoleic acid. SSI-4 induces lipid peroxidation, endoplasmic reticulum stress, DNA damage and activates apoptotic mechanisms. SSI-4 inhibits mTORC1 activity, suppresses B cell proliferation and antibody production, and induces autophagy. SSI-4 is applicable to research on cancers such as acute myeloid leukemia and renal cell carcinoma, as well as influenza infections .

HY-P10899

ETTAC-2	PROTACs TGF-beta/Smad	Endocrinology
ETTAC-2 is a LRG1 PROTAC degrader, degrading LRG1 via the ubiquitin-proteasome pathway with a DC₅₀ value of 8.38 μM. ETTAC-2 penetrates damaged renal cells to reduce the extracellular secretion of LRG1. ETTAC-2 effectively inhibits the TGF-β-Smad3 signaling pathway and diminishes the secretion of fibrosis-associated extracellular matrix proteins. ETTAC-2 degrades LRG1 within fibrotic kidneys and the efficacy in inhibiting the TGF-β-Smad3 pathway both in vitro and vivo. ETTAC-2 can be used for renal fibrosis research .

HY-19696B

Tauroursodeoxycholate dihydrate 100+ Cited Publications Tauroursodeoxycholic acid dihydrate; TUDCA dihydrate; UR 906 dihydrate	Caspase Apoptosis Endogenous Metabolite IRE1 NF-κB JNK Reactive Oxygen Species (ROS) Akt	Neurological Disease Metabolic Disease Inflammation/Immunology
Tauroursodeoxycholate dehydrate is an orally active taurine conjugate of Ursodeoxycholic acid (HY-13771). Tauroursodeoxycholate dehydrate inhibits caspase-3/7, Apoptosis, IRE1α/TRAF2/NF-κB, prevents JNK phosphorylation, inhibits ROS generation, and activates Akt signaling. Tauroursodeoxycholate dehydrate prevents cataract formation, reduces renal tubular damage in type 2 diabetic mice, reduces I/R injury in liver, and inhibits intestinal inflammation and barrier disruption in nonalcoholic fatty liver disease .

HY-B0639A

Amifostine trihydrate 10+ Cited Publications WR2721 trihydrate	MDM-2/p53 HIF/HIF Prolyl-Hydroxylase	Cancer
Amifostine trihydrate (WR2721 trihydrate) is a broad-spectrum cytoprotective agent and a radioprotector. Amifostine trihydrate selectively protects normal tissues from damage caused by radiation and chemotherapy. Amifostine trihydrate is potent hypoxia-inducible factor-α1 (HIF-α1) and p53 inducer. Amifostine trihydrate protects cells from damage by scavenging oxygen-derived free radicals. Amifostine trihydrate reduces renal toxicity and has antiangiogenic action .

HY-W002942

Ferroptosis-IN-21 1,2,3,4-Tetrahydroquinolin-8-ol; 8-hydroxy-1,2,3,4-tetrahydroquinoline	Ferroptosis Reactive Oxygen Species (ROS)	Inflammation/Immunology
Ferroptosis-IN-21 is a ferroptosis inhibitor that protects against renal I/R injury by suppressing ferroptosis and directly scavenging peroxyl radicals. Ferroptosis-IN-21 displays broad-spectrum anti-ferroptotic efficacy across multiple inducers in renal tubular epithelial cells, with nanomolar potency and robust suppression of lipid Reactive Oxygen Species (ROS). Ferroptosis-IN-21 significantly ameliorates renal I/R injury in mice, reducing histological damage, functional impairment, and inflammatory cytokine expression, while decreasing lipid peroxidation biomarkers such as 4-hydroxynonenal. Ferroptosis-IN-12 can be used for research in the field of ferroptosis-targeted drug development .

HY-173425

STING-IN-15	STING IFNAR TNF Receptor Interleukin Related	Inflammation/Immunology
STING-IN-15 is an orally active STING inhibitor, with an IC₅₀ of 116 nM against h-STING and an IC₅₀ of 96.3 nM against m-STING. STING-IN-15 inhibits the STING signaling pathway in cells, reduces the secretion of IFN-β and IP-10, downregulates the expression of ISG15, ISG56 and TNF-α, and suppresses the phosphorylation of TBK1/IRF3. STING-IN-15 alleviates systemic and renal inflammation induced by STING agonists in mice, reduces tissue damage and the expression of interferon pathway genes, and inhibits spontaneous tissue inflammation in mice. STING-IN-15 can be used for the research of acute kidney injury and autoimmune/inflammatory diseases .

HY-P10939A

Ac-DMLD-CMK TFA	Caspase Pyroptosis	Inflammation/Immunology Cancer
Ac-DMLD-CMK TFA is a caspase 3 inhibitor and a GSDME inhibitor. Ac-DMLD-CMK TFA binds directly to the catalytic domain of caspase-3, blocks caspase-3-mediated cleavage of GSDME, inhibits the activation of caspase 3 and Gsdme in the caspase 3-Gsdme signaling pathway, and reduces the levels of pyroptosis and apoptosis as well as the expression of LDH, IL-6, IL-1β and IL-18. Ac-DMLD-CMK TFA alleviates renal function deterioration, renal tubular epithelial cell injury, inflammatory cytokine secretion, pulmonary structural damage, and chemotherapy-induced nephrotoxicity .

HY-P6084

RP-220	NOD-like Receptor (NLR) p38 MAPK Apoptosis	Inflammation/Immunology
RP-220 is a renalase peptide targeting NLRP3. RP220 has anti-inflammatory and anti-apoptotic activities. RP220 inhibits renal tubular epithelial cells apoptosis with alkaline insult by activating MAPK signaling pathway. RP220 significantly inhibits NLRP3 expression and reduces macrophage infiltration and kidney tissue damage in acute kidney injury (AKI) mice model. RP-220 can be uses for systemic lupus erythematosus (SLE) and its complication lupus nephritis (LN) research .

HY-116568

Prothioconazole JAU-6476	Fungal Cytochrome P450 Microtubule/Tubulin Mitochondrial Metabolism DNA/RNA Synthesis Apoptosis Fatty Acid Synthase (FASN)	Infection Metabolic Disease Endocrinology
Prothioconazole is an orally active broad-spectrum fungicide. Prothioconazole weakly inhibits CaCYP51 activity in Candida albicans, with an apparent IC₅₀ of approximately 120 μM. Prothioconazole disrupts Microtubule stability by reducing the acetylation level of α-tubulin. Prothioconazole induces Mitochondrial dysfunction, oxidative stress, DNA damage, and Apoptosis. Prothioconazole accumulates ¹⁴-methylated sterols and depletes ergosterol in cells, culture media, plants, and animals. Prothioconazole interferes with pyruvate metabolism and glycolysis/gluconeogenesis processes in mouse liver, downregulates Fasn mRNA expression, and induces hepatotoxicity and renal metabolic disorders. Prothioconazole reduces the fertility of female mice. Prothioconazole inhibits body weight gain and increases liver/kidney indices in mice. Prothioconazole can be used in studies related to candidiasis .

HY-P10939

Ac-DMLD-CMK	Caspase Pyroptosis	Inflammation/Immunology Cancer
Ac-DmLD-CMK is a caspase 3 inhibitor and a GSDME inhibitor. Ac-DmLD-CMK binds directly to the catalytic domain of caspase-3, blocks caspase-3-mediated cleavage of GSDME, inhibits the activation of caspase 3 and Gsdme in the caspase 3-Gsdme signaling pathway, and reduces the levels of pyroptosis and apoptosis as well as the expression of LDH, IL-6, IL-1β and IL-18. Ac-DmLD-CMK alleviates renal function deterioration, renal tubular epithelial cell injury, inflammatory cytokine secretion, pulmonary structural damage, and chemotherapy-induced nephrotoxicity .

HY-W392413

Glutathione monoethyl ester	Drug Derivative Reactive Oxygen Species (ROS)	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology
Glutathione monoethyl ester is a glutathione derivative that can be transported into cells and hydrolyzed into glutathione. Glutathione monoethyl ester downregulates the gene expression of TEN1 and CTC1 while upregulating TERT expression. Glutathione monoethyl ester enhances telomerase activity, promotes proliferation and differentiation in aged bone marrow stromal cells, while elevating glutathione levels and reducing oxidative stress, protein aggregation and cell death in motor neuronal cells. Glutathione monoethyl ester confers broad multi-organ protection against cerebral ischemia, renal injury, liver damage, and pancreatitis. Glutathione monoethyl ester can be used for the research of amyotrophic lateral sclerosis, stroke, acute renal failure, liver injury, and acute pancreatitis .

HY-117804

8-Br-cADPR 8-Bromo-Cyclic ADP-Ribose	TRP Channel	Neurological Disease Metabolic Disease
8-Br-cADPR (8-Bromo-Cyclic ADP-Ribose), a cyclic adenosine diphosphate (ADP)-ribose (cADPR) antagonist, is a TRPM2 ion channel antagonist. 8-Br-cADPR reduces renal damage and the expression of caspase-3 and TRPM2 .

HY-164429

VIP236	Integrin Elastase	Cancer
VIP236 is a small-molecule drug conjugate targeting αvβ3 integrin. VIP236 achieves tumor homing via specific binding to αvβ3 integrin and delivers its payload to the tumor microenvironment. The linker of VIP236 is cleavable by neutrophil elastase, which is highly expressed in the tumor microenvironment, to release the payload 7-ethylcamptothecin. This payload induces DNA damage by inhibiting topoisomerase 1, thereby exerting anti-tumor effects. VIP236 exhibits excellent plasma stability and tumor targeting property, with a tumor/plasma payload ratio 10-fold higher than that of the single administration. It effectively induces tumor regression, reduces metastasis formation, and shows good tolerance in mouse models. VIP236 has been used in studies related to non-small cell lung cancer, clear cell renal cell carcinoma, colon cancer, triple-negative breast cancer, small cell lung cancer, and metastatic solid tumors .

HY-175081

8-Br-cADPR sodium salt 8-Bromo-Cyclic ADP-Ribose sodium salt	TRP Channel	Metabolic Disease
8-Br-cADPR (8-Bromo-Cyclic ADP-Ribose) sodium salt, a cyclic adenosine diphosphate (ADP)-ribose (cADPR) antagonist, is a TRPM2 ion channel antagonist. 8-Br-cADPR sodium salt reduces renal damage and the expression of caspase-3 and TRPM2 .

HY-134579

Chaetomellic acid A	Farnesyl Transferase	Inflammation/Immunology
Chaetomellic acid A can be isolated from Chaetomella acutiseta. Chaetomellic acid A is a specific inhibitor of farnesyl-protein transferase. Chaetomellic acid A decreases oxidative stress-induced apoptosis in cells. Chaetomellic acid A reduces renal damage after unilateral ureteral obstruction (UUO) in mice .

HY-117962

(Rac)-BI 703704	Guanylate Cyclase	Metabolic Disease
(Rac)-BI 703704 is a potent soluble guanylyl cyclase (sGC) activator. (Rac)-BI 703704 reduces progression of renal damage in the ZSF1 rat, and highlight the potential of sGC activation as an effective therapy for diabetic nephropathy .

HY-105271

S-312-d S-(+)-S-312-d	Calcium Channel	Others
S-312-d (S-(+)-S-312-d) is a calcium channel blocker with the activity of protecting the kidney from ischemic acute renal failure. S-312-d (0.01-0.1mg/kg b.wt. iv) administered before ischemia has a dose-dependent protective effect on ischemia-induced renal damage, improves the survival rate of ischemic rats, and reduces renal cortical edema and the increase in renal tissue calcium content.

HY-174318

NARS-3′	Xanthine Oxidase	Metabolic Disease
NARS-3′ is an orally active reversible xanthine oxidase (XO) inhibitor with the IC₅₀ of 21.01 μM. NARS-3′ can competitively inhibit XO activity and reduce uric acid production. NARS-3′ can reduce renal damage in hyperuricemia mice. NARS-3′ can be used for the study of hyperuricemia.

HY-176238

CX116	Apoptosis	Metabolic Disease Cancer
CX116 is an orally active anti-inflammatory agent. CX116 exerts its effects by inhibiting the inflammatory response, reducing oxidative stress, protecting mitochondrial function, and counteracting apoptosis. CX116 bears acceptable toxicity, and can significantly protect renal tissue from Cisplatin (HY-17394)-induced damage. CX116 can be used for the study of Cisplatin-induced acute kidney injury (cis-AKI) .

HY-169059

Ferroptosis-IN-12	Ferroptosis	Inflammation/Immunology
Ferroptosis-IN-12 (Cpd-A1) is a ferroptosis inhibitor. Ferroptosis-IN-12 exhibits effective ferroptosis inhibition in Erastin (HY-15763)-treated mouse tubular epithelial cells (mTECs) and improves kidney function, alleviates renal tubular damage, and reduces inflammation in a dose-dependent manner in acute kidney injury (AKI) mouse models induced by ischemia/reperfusion (I/R) or cecal ligation and puncture (CLP). Ferroptosis-IN-12 demonstrates good plasma stability and high distribution in kidney tissues in pharmacokinetic studies in mice. Ferroptosis-IN-12 holds promise for research in the field of acute kidney injury (AKI) .

HY-113298R

Citraconic acid (Standard) Methylmaleic acid (Standard)	Reference Standards NOD-like Receptor (NLR) Keap1-Nrf2 Reactive Oxygen Species (ROS)	Cardiovascular Disease Inflammation/Immunology
Citraconic acid (Methylmaleic acid) (Standard) is the analytical standard of Citraconic acid (HY-113298). This product is intended for research and analytical applications. Citraconic acid is an orally active inhibitor targeting the NLRP3 inflammasome and Keap1-Nrf2 pathway. Citraconic acid reduces reactive oxygen species (ROS) generation by inhibiting succinate dehydrogenase (SDH) activity. Citraconic acid also modifies the conformation of Keap1 protein, relieves its inhibition of Nrf2, promotes antioxidant gene expression, and inhibits NLRP3 activation and the release of pro-inflammatory factors such as IL-1β and IL-18. Citraconic acid has anti-inflammatory and antioxidant activities, can reduce oxidative stress and cell pyroptosis, improve tissue damage, and can be used for the research of inflammation-related diseases such as acute renal ischemia-reperfusion injury. Citraconic acid is an isomer of Itaconic acid (HY-Y052) .

HY-184000

SIRT5-IN-10	Sirtuin JAK STAT Interleukin Related	Endocrinology
SIRT5-IN-10 is a competitive SIRT5 inhibitor. SIRT5-IN-10 improves renal function and reduces histopathological damage in septic acute kidney injury (AKI) mice. SIRT5-IN-10 can be used for the research of sepsis-associated AKI .

HY-N17651

Tricetinidin chloride	Reactive Oxygen Species (ROS) Fc Receptor (FcR) Heme Oxygenase (HO)	Inflammation/Immunology
Tricetinidin chloride is an antioxidant. Tricetinidin chloride protects rat renal cells against oxidative stress and DNA damage by reducing ROS production, increasing GSH levels, restoring mitochondrial membrane potential, and upregulating HO-1 expression. Tricetinidin chloride also inhibits the expression of IgE receptors on human mast cells. Tricetinidin chloride can be used in the research of inflammatory and allergic diseases .

HY-P992101

Aritinercept AUR-200	TNF Receptor IFNAR Interleukin Related	Inflammation/Immunology
Aritinercept (AUR-200) is a recombinant fusion protein targeting TNFSF13B/BAFF/CD257. Aritinercept neutralizes BAFF and APRIL (TNFSF13), reduces B cell proliferation, suppresses peripheral B cells, lowers serum immunoglobulins. Aritinercept reduces renal damage markers, decreases IFNγ, IL-17A, and anti-dsDNA autoantibodies, and improves survival in a mouse model of SLE. ritinercept can be used for the research of systemic lupus erythematosus .

HY-N18656

Terminalia chebula extract	Bacterial	Infection
Terminalia chebula extract, derived from the fruit of the Terminalia chebula tree. Rich in bioactive compounds such as tannins, flavonoids, phenols, and organic acids like gallic acid and ellagic acid, this extract demonstrates a wide range of pharmacological activities. It acts as a natural laxative, supports digestive health, and exhibits potent antioxidant, anti-inflammatory, and antibacterial properties, effectively targeting various pathogenic bacteria, including Helicobacter pylori, Staphylococcus aureus, and Escherichia coli. Terminalia Chebula Extract also shows significant hepatoprotective effects, shielding the liver from damage through antioxidant and anti-inflammatory mechanisms. It has nephroprotective properties, alleviating renal dysfunction and enhancing kidney health by modulating inflammatory pathways. Additionally, the extract demonstrates neuroprotective activity, reducing neuronal damage and improving memory function. It has potential anti-diabetic effects, enhancing glucose uptake and reducing oxidative stress.

HY-181077

AMPKα1 activator 1	AMPK	Endocrinology
AMPKα1 activator 1 is a selective and orally active AMPKα1 activator with an EC₅₀ of 35.1 nM. AMPKα1 activator 1 shows 176-fold selectivity over AMPKα2. AMPKα1 activator 1 can be used as a cell protectant and a kidney protectant. AMPKα1 activator 1 attenuates elevation of serum creatinine and blood urea nitrogen levels, alleviates kidney damage, and reduces cellular infiltration in renal ischemia-reperfusion injury contexts. AMPKα1 activator 1 can be associated with renal ischemia-reperfusion injury research .

Cat. No.	Product Name

HY-L229

Nephrotoxicity Compound Library	158 compounds
Kidneys are one of the vital organs in the human body. Due to their exposure to higher concentrations of circulating drugs or metabolites, they are highly susceptible to drug-induced renal injury (DIRI). According to statistics, drug-induced kidney injury accounts for approximately 20% of nephrotoxicity reports and can lead to acute kidney injury (AKI), chronic kidney disease (CKD), or even end-stage renal disease (ESRD). Early detection of drug nephrotoxicity is crucial for preventing irreversible kidney damage. Research into its mechanisms can help optimize clinical medication by adjusting dosages or avoiding combinations of nephrotoxic drugs. Additionally, predicting drug-induced nephrotoxicity in early drug development can reduce the risk of late-stage R&D failure. MCE offers 158 nephrotoxicity compounds that have been clearly reported by the FDA to be associated with kidney injury. This library can be used for studying molecular mechanisms of nephrotoxicity or developing novel biomarkers.

Nephrotoxicity Compound Library

158 compounds

Kidneys are one of the vital organs in the human body. Due to their exposure to higher concentrations of circulating drugs or metabolites, they are highly susceptible to drug-induced renal injury (DIRI). According to statistics, drug-induced kidney injury accounts for approximately 20% of nephrotoxicity reports and can lead to acute kidney injury (AKI), chronic kidney disease (CKD), or even end-stage renal disease (ESRD). Early detection of drug nephrotoxicity is crucial for preventing irreversible kidney damage. Research into its mechanisms can help optimize clinical medication by adjusting dosages or avoiding combinations of nephrotoxic drugs. Additionally, predicting drug-induced nephrotoxicity in early drug development can reduce the risk of late-stage R&D failure.

MCE offers 158 nephrotoxicity compounds that have been clearly reported by the FDA to be associated with kidney injury. This library can be used for studying molecular mechanisms of nephrotoxicity or developing novel biomarkers.

HY-L145

Antihypertensive Compound Library	893 compounds
The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death. Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs). MCE offers a unique collection of 893 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

Antihypertensive Compound Library

893 compounds

The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death.

Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs).

MCE offers a unique collection of 893 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

Cat. No.	Product Name	Target	Research Area